Kornimate/medical-research-clean huggingface dataset:
preoperative single glucocorticoid hip fracture hip fracture surgery

Conditions: Delirium - Postoperative; Stress, Physiological

Summary: the study is a double-blinded, randomized, placebo-controlled trials. the objective is to investigate the effect of single-high-dose glucocorticoid on surgical stress response and postoperative delirium among elderly hip fracture patients undergoing surgery.

patients with hip fracture are exposed for two traumas that can trigger a stress response. the first is the fall that causes the fracture. the second is the surgery. in this study the intervention is dispensed early in the disease course - as soon as the fracture has been diagnosed and booked for surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing surgery for hip fracture * informed signed consent * danish speaking exclusion criteria: * allergies towards contents of solu-medrol * insulin dependent diabetes * glaucoma * in treatment for cancer disease * positive hiv, hepatitis b or c status * lack of informed consent (eq. severe dementia, coma, and others) * current treatment with systemic glucocorticoids (pr.os or intravenous) immunoinflammatory disease (except topical treated skin disease and respiratory disease) * current immunosuppressive treatment * unable to participate in cam-s measurement * peptic ulcera
a study to assess efficacy, long term safety and tolerability of rt001 in subjects with friedreich's ataxia

Conditions: Friedreich's Ataxia

Summary: the purpose of this study is to assess the efficacy, long term safety and tolerability of rt001 in subjects with friedreich's ataxia

this is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, in subjects with frda following the oral administration of study drug (active or placebo capsules). sixty eligible patients will undergo various assessments at different time points during the the study. the study duration is 13 months which includes screening, treatment and safety follow up phone call.

Eligibility criteria:
key inclusion criteria: 1. male or female 12 to 50 years of age 2. medical history consistent with the symptoms of frda at ≤ 25 years of age 3. detection of biallelic pathogenic variants in frataxin gene (fxn) 4. ambulatory (with or without assistive device) and capable of performing other assessments/evaluations. 5. must be able to walk 25 feet during the timed 1-minute walk key exclusion criteria: 1. received treatment with other experimental therapies within the last 30 days prior to the first dose 2. previously participated in the rt001 trial 3. refusal to discontinue fish oils or other oil-based supplements for the duration of the study (screening till last study procedure completed) 4. history of malignancies (other than basal cell carcinomas) 5. inability to complete cpet protocol 6. female who is breastfeeding or has a positive pregnancy test 7. history of uncontrolled diabetes mellitus (type 1 or 2)
alterations in intestinal microbiota, metabolites, and immune cells in allo-hsct

Conditions: Graft Vs Host Disease

Summary: this research project delves into the critical role of gut immunity in the occurrence and progression of acute graft-versus-host disease (agvhd) post allogeneic hematopoietic stem cell transplantation (allo-hsct). addressing the current gaps in understanding the involvement of intestinal microbiota, metabolites, and cellular metabolism in clinical agvhd, the study involves comprehensive analyses on 200 allo-hsct patients and 50 healthy volunteers. by scrutinizing changes in gut microbiota, metabolites, and immune cell metabolism, the research aims to shed light on their roles in allo-hsct and their correlation with post-transplant complications. the findings are poised to offer crucial insights for diagnosing and prognosticating complications following transplantation.

the intestinal immune system plays a pivotal role in the onset, progression, and evolution of acute graft-versus-host disease (agvhd) following allogeneic hematopoietic stem cell transplantation (allo-hsct). however, the precise contributions and mechanisms underlying the involvement of intestinal microbiota, metabolites, and cellular metabolism in immune regulation during clinical agvhd remain unclear. this research initiative aims to collect peripheral blood, fecal, and urine samples from 200 patients before and after transplantation as well as 50 healthy volunteers. comprehensive analyses, including metagenomics, 16s rrna sequencing, transcriptomics, metabolomics, single-cell sequencing, as well as assessments of immune cell function and inflammatory cytokines, will be conducted. additionally, longitudinal follow-up observations will be performed to monitor post-transplant complications, relapse and immune reconstitution. by investigating the dynamics of gut microbiota, metabolites, and cellular metabolism and analyzing their correlation with changes in immune responses, this study seeks to elucidate the roles of intestinal microbiota, metabolites, and immune cell metabolism in the context of allo-hsct. the findings are anticipated to provide insights into the correlation between these factors and outcomes of allo-hsct patients, contributing valuable evidence for the diagnosis and prognosis assessment of complications following transplantation.

Eligibility criteria:
inclusion criteria: * patients with hematologic disorders undergoing allo-hsct. exclusion criteria: * patients with confirmed pathogenic intestinal infections and severe systemic infections at the time of sampling. * diagnosis of autoimmune diseases, metabolic disorders, and chronic gastrointestinal diseases. * pre-transplant diseases not in complete remission. * post-transplant hematopoietic engraftment failure or pre-engraftment mortality.

Keywords: allo-hsct intestinal microbiota metabolites immunity
a registered cohort study on brain calcification

Conditions: Brain Calcification

Summary: brain calcification is a common neuroimaging feature in patients with metabolic, neurological, or developmental disorders, infectious diseases, traumatic or toxic history, as well as in otherwise normal older people. to understand the clinical and genetic characteristics of brain calcification, we establish a cohort of brain calcification to follow up patients with brain calcification.


Eligibility criteria:
inclusion criteria: * patients with brain calcium deposit(s) based on examinations of ct scans * patients with total calcification score(tcs) greater than the physiological threshold * relatives of brain calcification patients. * unrelated healthy controls * participants or parent(s)/legal guardian(s) willing and able to complete the informed consent process exclusion criteria: * brain calcification caused by specific secondary factors such as infection, poisoning, and trauma * participants declining or unable to comply with trial procedures and visit schedule

Keywords: brain calcification natural history genetics
sentence production training in aphasia

Conditions: Aphasia

Summary: this project focuses on developing a novel treatment for sentence production and comprehension in aphasia, using implicit priming. first set of experiments will aim examine which learning conditions are most effective in creating maximal training gains. then, in a later study, the investigators will develop and test the efficacy of a novel treatment study based on findings from the first set of the studies.

over five years, the investigators will conduct a series of studies to develop a novel intervention strategy for improving sentence production and comprehension in persons with aphasia. specifically, the investigators will use implicit learning of grammar as a novel facilitator for language recovery in aphasia. the planned studies seek to test the hypothesis that implicit learning alters the central language system in pwa, creating lasting and generalized improvements in both sentence production and comprehension. aim 1 will determine the extent to which different learning conditions modulate immediate and long-term improvement in sentence production. the investigators integrate multiple theories of language learning and apply them to make predictions about the trajectory of priming-induced learning in pwa. in aim 2, using a set of eyetracking and sentence comprehension tasks, it will be investigated whether the effects of priming in production generalize to off-line (accuracy) and on-line (eye fixations) sentence comprehension and determine which learning conditions result in greater cross-modality generalization. in aim 3, the investigators will develop and establish phase i efficacy data of an implicit priming treatment, incorporating the crucial learning conditions supporting maximal retention from aims 1 and 2. the project will recruit both individuals with aphasia and without aphasia.

Eligibility criteria:
inclusion criteria: * individuals with post-stroke aphasia * at least 6 months post-onset of eft hemisphere stroke * native speaker of english * normal or corrected to normal hearing and vision * high-school educated * difficulty communicating in sentences, with some ability to use words independently exclusion criteria: * severe apraxia of speech * other neurological conditions affecting communication (e.g., dementia) * uncontrolled psychiatric/psychological conditions affecting thinking and communication * active alcohol/substance abuse

Keywords: aphasia training aphasia treatment sentences grammar
effect of sunlight exposure and outdoor activities on depression, cognition and quality of life in the elderly

Conditions: Aging; Nursing Homes; Depression in Old Age; Cognitive Impairment; Quality of Life

Summary: background: the transition to long-term care facility can be a stressful and emotional event for the elderly. the evidences showed that the prevalence of depression and the cognition impairment were higher in the institutionalized elderly than the community dwelling elderly. it could affect the quality of life of the elderly and increase risk of mortality. purpose: the aim of the study is to evaluate the effect of outdoor activities and sunlight exposure on depression, cognitive function, and quality of life among institutionalized elderly. method: the design is a randomized control trial. participants will be randomly allocated to experimental or control groups by block randomization. in the experimental group, participants will be encouraged to reduce time spent on bed and bedroom. nurses, nurse aids or family will take participants outdoors and exposure their face, hands or arm to sunlight for 15-30 minutes a day, five days a week for three months (if the uv index is over 8 according to the forecast of center weather bureau, the participants will be asked to stay inside). in the control group, the participants will receive routine care. the control group will neither be encouraged to stay outdoors nor limit the chance to exposure to sunlight. expected outcome: the expected benefit of the research is to improve the depression, cognitive function, and quality of life of the institutionalized elderly.


Eligibility criteria:
inclusion criteria: * resident in the long-term care facility for at least 6 months * barthel index score is equal or over 20 * able to communicate * life expectancy over 12 months * conscious clear exclusion criteria: * allergy to sunlight * diagnosed with skin cancer

Keywords: sunlight exposure institutionalized elderly depression quality of life cognition function
effect of tadalafil in chronic obstructive lung disease patients suffering from secondary pulmonary hypertension

Conditions: Chronic Obstructive Lung Disease

Summary: tadalafil may lower the pulmonary artery pressure in patients with chronic obstructive lung disease and secondary pulmonary hypertension and thereby improve patients quality of life.

twenty outpatients with chronic obstructive lung disease (copd) and secondary pulmonary hypertension are treated in a cross-over design with tadalafil or placebo for 4 weeks. primary effect parameter is 6 min. walking test.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic obstructive lung disease exclusion criteria * patients with asthma
a multicenter, open-label trial to assess subject preference of parcopa, carbidopa/levodopa orally disintegrating tablets, compared to conventional carbidopa/levodopa tablets in subjects with stable parkinson's disease

Conditions: Parkinson's Disease

Summary: the objective of this trial was to assess subject preference for parcopa, carbidopa/levodopa orally disintegrating tablets (odt), compared with conventional carbidopa/levodopa tablets, in subjects with stable parkinson's disease.

see approved package insert for adverse event information.

Eligibility criteria:
inclusion criteria: * stable parkinson's disease exclusion criteria: * not using carbidopa/levodopa tablets
digital home-exercise therapy application for patients with non-surgical knee injuries

Conditions: Knee Injuries; Knee Osteoarthritis; Patellofemoral Syndrome

Summary: knee pain is one of the most prevalent musculoskeletal disorders in the united states. conservative treatments generally consist of pharmacological agents and physical therapy. unfortunately, such conservative care is often mismanaged, and little data is collected on clinical outcomes. the proposed investigation utilizes a novel and state-of-the-art mobile application (detp) to guide an at-home exercise therapy program for non-operative knee pain. the purpose of this study is conducting a single-blind randomized, controlled, superiority study to compare the detp to conventional physical therapy (pt). the investigators will seek to determine improvement in pain and function in promis measures as the primary outcome. the investigators will also evaluate satisfaction with the application as a secondary outcome.


Eligibility criteria:
inclusion criteria: * age 18-75, inclusive. * diagnosis of knee injury. for participants enrolled from the mayo healthcare system database, knee injury identified from electronic medical records. * pain numerical rating scale score of 4 or greater on a 0-10 scale (0 = no pain, 10 = pain). * participants must be diagnosed with a knee injury and the next step of care is either a home exercise program or external physical therapy ordered at the academic center. * prescribed external physical therapy (i.e., therapy not completed at mayo clinic in rochester/minneapolis). exclusion criteria: * no access to android or iphone smartphone * bmi greater than or equal to 35 * previously completed series of physical therapy visits for knee injury within the past 12 months for the same injury (received one introduction pt session as seen in executive program will not be considered an exclusion). * recommended by a physician for consideration of total knee replacement. * diagnosis of rheumatoid arthritis, fibromyalgia, gout in the knee, or other systemic rheumatic disease. * hospitalization for a stroke, heart attack, heart failure, or had surgery for blocked arteries in the past 12 months. * total joint replacement knee surgery, bucket-handle meniscus tear, acl tear, or other knee surgery in the past 12 months. * unable to speak english. * active diagnosis of psychosis. * fall history deemed by a physician to impose risk for potential injury with participation in a home-based exercise program. * severely impaired hearing or speech.

Keywords: knee pain knee osteoarthritis patellofemoral syndrome physical therapy digital health
research on the early warning model of children asthma acute attack based on wearable wrist smart device of huami

Conditions: Asthma in Children

Summary: childhood asthma is the most common chronic respiratory disease in childhood. the essence of asthma is chronic airway inflammation and airway hyperresponsiveness.the physiological characteristics of children and adults are very different, and the compensatory ability is very strong. there are often no obvious symptoms at the early stage of attack, or only intermittent or persistent cough of different degrees, without typical chest tightness and asthma.however, at this time, certain physiological indicators such as blood oxygen, heart rate, respiratory rate may have been significantly abnormal.if the disease continues to deteriorate and progresses to decompensation, it can quickly move from an asymptomatic state to a failure stage.therefore, dynamic and accurate acquisition of real-time vital signs and assessment is of great significance for early warning and improvement of prognosis of asthma attacks in children.intelligent wearable devices can be used to acquire real-time physiological index data of users, such as heart rate, blood oxygen, exercise and sleep dynamic data.an in-depth analysis of long-term and multi-scene dynamic data before and after asthma attacks can establish an early warning model for children with acute asthma attacks by wearable wrist smart devices, which may provide important help for severity assessment, follow-up tracking and out-of-hospital prevention and control of the disease.

this project is selected 200 cases of children with asthma diagnosis definitely, collection and heart rate, blood oxygen, exercise and sleep dynamic data, followed up for 3 to 6 months (at least 3 months), records of clinical asthma attacks and clinical data, through the cloud data analysis and deep learning, analysis of children with asthma attacks and multiple physiological parameters (heart rate, blood oxygen, movement and the dynamic data of sleep, etc.), the connection between the building of asthma early warning and illness severity hierarchical evaluation model.then choose 200 cases of diagnosis in clinical practice to determine follow-up, patients with asthma children to observe to verify the exactness of the model of asthma attack early warning, and according to the collected data to further improve, calibration model, designed to provide children with family members and medical personnel of an asthma attack warning and follow-up management wearable auxiliary equipment and management platform.

Eligibility criteria:
inclusion criteria: clinical diagnosis of asthma. exclusion criteria: severe chronic diseases with organ dysfunction and dyspnea.

Keywords: wearable wrist smart device
allogeneic stem cell transplant with alpha/beta t and b cell depletion for hematologic malignancies

Conditions: Leukemia; Lymphoma; Myelodysplasia

Summary: this is a single arm pilot study for patients using α/β t cell-depleted peripheral stem cell transplantation (psct) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (pscs) using the clinimacs system for t cell depletion plus cd19+ b cell depletion to determine efficacy as determined by engraftment and graft versus host disease (gvhd), and one year leukemia free survival.


Eligibility criteria:
inclusion criteria: 1. leukemias/lymphomas * acute myeloid leukemia, primary or secondary disease status: remission or \<10% bone marrow blasts * myelodysplasia * acute lymphoblastic leukemia disease status: in hematologic remission * chronic myelogenous leukemia disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase. * mixed lineage or biphenotypic acute leukemia * lymphoblastic lymphoma disease status: remission * burkitt's lymphoma/leukemia: disease status- in remission 2. acceptable organ status clearance 3. no active untreated infection. patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic 4. signed informed consent. 5. negative pregnancy test for females of childbearing potential. exclusion criteria: 1. patients who do not meet disease, organ or infectious criteria. 2. no suitable donor 3. received previous allogeneic transplant donor must be either unrelated, mismatched up to one antigen/one antigen and one allele or a related, hla match other than a sibling.

Keywords: transplant alternative donor
combination of erlotinib and bevacizumab as second-line treatment in patients with non-small cell lung cancer

Conditions: Non-small-cell Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy and toxicity of combination of erlotinib and bevacizumab in patients with locally advanced or metastatic, non-squamous non-small cell lung cancer, who progressed after first line treatment. pretreatment with one of the two agents would not excluded patients from the study, in order to evaluate whether the combination of the two biologic agents could reverse tumor resistance.

a randomized, placebo-controlled phase iii trial of erlotinib versus placebo, demonstrated that therapy with this tyrosine kinase inhibitor (tki) prolongs survival after first or second line therapy in patients with advanced nsclc. moreover, the addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor bevacizumab (vegf), to systemic chemotherapy, improved both the response rates and the time to tumor progression in two trials. early data from phase i/ii trials examining the combination of these two biological agents in pre-treated patients with non-squamous nsclc, showed no major pharmacokinetic interactions and promising clinical activity.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed, unresectable locally advanced (stage iiib with pleural effusion) and/or metastatic (stage iv) nsclc * progression to first-line therapy for advanced/metastatic nsclc * bi-dimensionally measurable disease (not included in radiation field) * ecog performance status of 0-2 * life expectancy of more than 6 months * adequate liver (serum bilirubin \<1.5 times the upper normal limit, ast and alt \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases,adequate renal function (serum creatinine \<1.5 times the upper normal limit),and bone marrow (neutrophils ≥ 1.5x 109 /l, and platelets ≥ 100x 109 /l) function * signed informed consent exclusion criteria: * central nervous system involvement (unless if the patient has being previously irradiated and is clinically stable) * presence of a centrally located mass or a tumor mass in close relation to large vessels or a mass with cavitation. * surgery or radiation therapy within the last 14 days from study entry * active infection * history of life-threatening hemoptysis / hematemesis, history of thrombosis or use of anti-coagulation therapy * history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) or stroke within the previous 6 months or uncontrolled hypertension * patients on other experimental treatment protocols * history of a second primary malignancy (other than basal-cell skin carcinoma or in situ carcinoma of the cervix) * psychiatric illness or social situation that would preclude study compliance * pregnant or lactating women

Keywords: nsclc tki's anti-vegf